<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470533</url>
  </required_header>
  <id_info>
    <org_study_id>NL51318.078.14</org_study_id>
    <nct_id>NCT02470533</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma</brief_title>
  <acronym>TRENDY</acronym>
  <official_title>Transarterial Chemoembolization With Drug-Eluting Beads (Standard Arm) Versus Stereotactic Body Radiation Therapy (Experimental Arm) for Hepatocellular Carcinoma: A Multicenter Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      This study will compare head to head in patients with hepatocellular carcinoma (HCC)
      ineligible for surgery or radiofrequency ablation, the standard treatment arm, transarterial
      chemoembolization with drug-eluting beads (TACE-DEB), with the experimental arm, stereotactic
      body radiation therapy (SBRT). The investigators hypothesis is that the time to progression
      is more favorable after SBRT than after TACE-DEB. The expected time to include the required
      patients for this trial will be four years.

      To the best of the investigators knowledge this study will be the first in the world that
      will compare both techniques in a randomized trial.

      Objective:

      To assess the time to progression after TACE-DEB and after SBRT in a comparable population of
      patients diagnosed with HCC.

      Study design:

      Randomized, prospective, open-label, and phase II study.

      Study population:

      Patients diagnosed with HCC, Child-Pugh grade A, one to three tumors, cumulative diameter ≤
      6cm, and ≥ 18 years old.

      Intervention:

      Patients with HCC will be randomized to receive the standard treatment, TACE-DEB loaded with
      doxorubicin or the experimental arm, SBRT.

      Main study parameters/endpoints:

      The primary endpoint of this study will be time to progression, defined as time from
      randomization to radiological progression.

      Secondary endpoints will be:

        -  Time to local recurrence

        -  Response rate (complete and partial response)

        -  Overall survival

        -  Toxicity

        -  Quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary liver cancer, particularly hepatocellular carcinoma (HCC) is a major health problem.
      Curative therapies for HCC are considered hepatic resection, liver transplantation and
      radiofrequency ablation (RFA). Hepatic resection is preferred for patients with limited
      disease, non-cirrhotic livers or selected patients with Child-Pugh A cirrhosis. Unlike
      resection, liver transplantation treats the tumor and the underlying cirrhosis present in the
      liver. Candidates for liver transplantation are preferably those with cirrhosis and tumors
      that comply with the Milan criteria (single tumor &lt;5cm or 1-3 tumors each of ≤ 3cm). Because
      most patients are not amenable to resection or liver transplantation, RFA has emerged as an
      effective treatment option. RFA is limited by the location of the tumor in the liver and by
      the tumor size with best results after RFA achieved for tumors ≤3cm. For patients that are
      not eligible for RFA due to large or multifocal tumors, transarterial chemoembolization with
      drug-eluting beads (TACE-DEB) is the preferred treatment.

      Stereotactic body radiation therapy (SBRT) delivers a highly effective dose of irradiation to
      the tumor while maximally avoiding dose delivery to surrounding healthy structures. SBRT is
      offered as an ablative local treatment with reported high percentages of complete and partial
      responses with limited toxicity.

      An international expert committee on HCC has recommended time to progression (TTP) as primary
      endpoint for phase II randomized trials. Although data is scarce the best published median
      TTP after TACE-DEB was 16 months and after SBRT 36.5months in a more or less comparable
      patient population (Barcelona Clinic Liver Cancer stage system A-C).

      The present study will include patients not eligible for resection or RFA. Patients may be
      eligible for bridging or for down staging to transplantation. Well compensated liver
      cirrhosis (Child-Pugh A) and disease confined to the liver (one to three tumors cumulative
      diameter ≤ 6cm) is required. To our knowledge this trial will be the first in the world to
      compare TACE-DEB and SBRT. This trial may have a big impact on the control of the disease and
      may contribute to change the standard of care from a palliative to a more radical/curative
      intention in this patient population
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to local recurrence</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>4 years</time_frame>
    <description>Common toxicity criteria v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 years</time_frame>
    <description>EORTC Quality of life forms C-30 and HCC-18, Quality of life form Euro QoL5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) &lt; of 5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>6 fractions of 8-9Gy</description>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>chemoembolization</intervention_name>
    <description>Up to 4 sessions</description>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with HCC Patients can be included if they require treatment prior
             to liver transplantation.

          -  Barcelona Clinic Liver Cancer Stage System class A-B

          -  One to three tumors of maximum cumulative diameter ≤ 6 cm measured in all 3 axes.

          -  Measurable disease to be selected as a target on CT/MRI-scan, according to mRECIST
             criteria for HCC within 6 weeks prior to randomization (≥ 1cm at least in one
             dimension, suitable for repeated measurement, and arterial enhancement) [44].

          -  Tumor visibility on CT

          -  Child-Pugh A cirrhosis

          -  Age ≥ 18 years

          -  ECOG performance status 0-1

          -  Albumin&gt; 28 g/l, bilirubin &lt; 50 µmol/l, INR &lt; 2.3, AST/ALT &lt; 5 times ULN, within 6
             weeks prior to randomization

          -  Platelets will be preferably ≥ 50x10E9/ l (if not, thrombocytes transfusion is allowed
             to ensure a safe procedure at the discretion of the interventional radiologist and
             gastroenterologist). Leukocytes &gt; 1.5x10E9/l, Hb &gt; 6 mmol/l, within 6 weeks prior to
             randomization

          -  Written informed consent

          -  Willing and able to comply to the follow-up schedule

          -  Planned to start treatment within 6 weeks from randomization.

        Exclusion Criteria:

          -  Eligibility for resection or RFA

          -  More than three tumors in the liver

          -  Ascites

          -  Any signs of acute viral or non-viral hepatitis

          -  Encephalopathy

          -  Vascular tumor invasion (contact with the vessel will not be considered
             contraindication).

          -  Previous radiotherapy to the liver

          -  Known current pregnancy

          -  Distance from the tumor to the esophagus, stomach, duodenum, small bowel or large
             bowel &lt; 0.5 cm on CT or on MRI (randomization imaging). Depending on the SBRT
             technique used, the minimum acceptable distance may vary and be larger for one
             technique compared to the other

          -  Uncontrolled portal hypertension (high bleeding risk). If gastroscopy has been
             performed, untreated esophageal varices grade III or IV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandra Mendez Romero, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriaan Moelker, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alejandra Mendez Romero, MD PhD</last_name>
    <phone>+31107040141</phone>
    <email>a.mendezromero@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriaan Moelker, MD PhD</last_name>
    <phone>+31107032886</phone>
    <email>a.moelker@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Vanwolleghem, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Reinhilde Weytjens, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thomas Vanwolleghem, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reinhilde Weytjens, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier d'Archambeau, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Verslype, Prof</last_name>
    </contact>
    <contact_backup>
      <last_name>Karin Haustermans, Prof</last_name>
    </contact_backup>
    <investigator>
      <last_name>Chris Verslype, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karin Haustermans, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Cattan, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Xavier Mirabell, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Stephane Cattan, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Mirabell, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>ZH</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Mendez Romero, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Adriaan Moelker, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Alejandra Mendez Romero</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriaan Moelker</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrike Westerveld, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Otto van Delden, Prof</last_name>
    </contact_backup>
    <investigator>
      <last_name>Henrike Westerveld, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Otto van Delden, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU MC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Haasbeek, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martijn Meijerink, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Niels Haasbeek, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martijn Meijerink, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Burgmans, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mieneke Coenraad, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mark Burgmans, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mieneke Coenraad, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Neelis, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastro</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Buijsen, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jeroen Buijsen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith de Vos-Geelen, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Peter Jansen, Prof</last_name>
    </contact_backup>
    <investigator>
      <last_name>Judith de Vos-Geelen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Jansen, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Tjwa, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sjoerd Jenniskens, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Eric Tjwa, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sjoerd Jenniskens, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Braam, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco van Vulpen, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Karel van Erpecum, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marco van Vulpen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karel van Erpecum, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Alejandra Mendez Romero</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

